NASDAQ:EDGE - Edge Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.89 -0.01 (-1.11 %)
(As of 05/25/2018 01:01 PM ET)
Previous Close$0.90
Today's Range$0.89 - $0.90
52-Week Range$0.84 - $17.77
Volume3,250 shs
Average Volume1.05 million shs
Market Capitalization$27.32 million
P/E Ratio-0.54
Dividend YieldN/A
Beta3.98

About Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics logoEdge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Receive EDGE News and Ratings via Email

Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDGE
CUSIPN/A
Phone800-208-3343

Debt

Debt-to-Equity RatioN/A
Current Ratio2.35
Quick Ratio2.35

Price-To-Earnings

Trailing P/E Ratio-0.54
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book0.63

Profitability

EPS (Most Recent Fiscal Year)($1.67)
Net Income$-50,850,000.00
Net MarginsN/A
Return on Equity-85.64%
Return on Assets-59.31%

Miscellaneous

Employees38
Outstanding Shares31,250,000

Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics (NASDAQ:EDGE) posted its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.14. View Edge Therapeutics' Earnings History.

When is Edge Therapeutics' next earnings date?

Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Edge Therapeutics.

What price target have analysts set for EDGE?

2 Wall Street analysts have issued twelve-month price targets for Edge Therapeutics' shares. Their forecasts range from $17.00 to $17.00. On average, they expect Edge Therapeutics' stock price to reach $17.00 in the next year. View Analyst Ratings for Edge Therapeutics.

Are investors shorting Edge Therapeutics?

Edge Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totalling 2,311,728 shares, an increase of 54.8% from the April 13th total of 1,493,401 shares. Based on an average trading volume of 2,024,591 shares, the short-interest ratio is currently 1.1 days. Currently, 10.9% of the company's shares are short sold.

Who are some of Edge Therapeutics' key competitors?

Who are Edge Therapeutics' key executives?

Edge Therapeutics' management team includes the folowing people:
  • Mr. Brian A. Leuthner, Co-Founder, Chief Exec. Officer, Pres and Director (Age 53)
  • Dr. R. Loch MacDonald M.D., Ph.D., Co-Founder, Chief Scientific Officer and Director (Age 56)
  • Dr. Herbert J. Faleck D.O., Chief Medical Officer (Age 65)
  • Mr. Andrew Saik, Chief Financial Officer (Age 49)
  • Mr. Daniel Brennan, Chief Operating Officer (Age 50)

Has Edge Therapeutics been receiving favorable news coverage?

News headlines about EDGE stock have trended somewhat positive this week, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Edge Therapeutics earned a daily sentiment score of 0.07 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Edge Therapeutics' major shareholders?

Edge Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (9.13%), BlackRock Inc. (3.77%), Wells Fargo & Company MN (0.36%), Algert Global LLC (0.36%) and Element Capital Management LLC (0.35%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Brian A Leuthner, James J Loughlin, R Loch Macdonald and W Bradford Middlekauff. View Institutional Ownership Trends for Edge Therapeutics.

Which institutional investors are buying Edge Therapeutics stock?

EDGE stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, BlackRock Inc., Algert Global LLC, Element Capital Management LLC and Wells Fargo & Company MN. Company insiders that have bought Edge Therapeutics stock in the last two years include James J Loughlin and W Bradford Middlekauff. View Insider Buying and Selling for Edge Therapeutics.

How do I buy shares of Edge Therapeutics?

Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edge Therapeutics' stock price today?

One share of EDGE stock can currently be purchased for approximately $0.89.

How big of a company is Edge Therapeutics?

Edge Therapeutics has a market capitalization of $27.32 million. The biotechnology company earns $-50,850,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. Edge Therapeutics employs 38 workers across the globe.

How can I contact Edge Therapeutics?

Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]


MarketBeat Community Rating for Edge Therapeutics (EDGE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Edge Therapeutics (NASDAQ:EDGE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Edge Therapeutics in the last 12 months. Their average twelve-month price target is $17.00, suggesting that the stock has a possible upside of 1,810.11%. The high price target for EDGE is $17.00 and the low price target for EDGE is $17.00. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 1.501.502.672.50
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.00$17.00$22.6667$25.50
Price Target Upside: 1,810.11% upside1,197.71% upside112.63% upside171.28% upside

Edge Therapeutics (NASDAQ:EDGE) Consensus Price Target History

Price Target History for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ:EDGE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Credit Suisse GroupDowngradeOutperform ➝ Underperform$17.00HighView Rating Details
3/28/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformN/AView Rating Details
3/3/2017Leerink SwannReiterated RatingOutperform ➝ Outperform$21.00N/AView Rating Details
3/3/2017GuggenheimReiterated RatingBuy ➝ In-Line$30.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Edge Therapeutics (NASDAQ:EDGE) Earnings History and Estimates Chart

Earnings by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ:EDGE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.53)($0.53)($0.53)
Q2 20181($0.52)($0.52)($0.52)
Q3 20181($0.51)($0.51)($0.51)
Q4 20181($0.54)($0.54)($0.54)

Edge Therapeutics (NASDAQ EDGE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018($0.53)N/AView Earnings Details
5/1/20183/31/2018($0.53)($0.67)ViewN/AView Earnings Details
3/1/2018Q4 2017($0.43)($0.45)ViewListenView Earnings Details
11/1/2017Q3 2017($0.48)($0.37)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.4370)($0.44)ViewListenView Earnings Details
5/3/2017Q1 2017($0.4230)($0.42)ViewListenView Earnings Details
3/2/2017Q4 2016($0.42)($0.33)ViewListenView Earnings Details
11/1/2016Q3 2016($0.38)($0.37)ViewN/AView Earnings Details
8/3/2016Q2($0.38)($0.33)ViewListenView Earnings Details
5/3/2016Q1 2016($0.34)($0.32)ViewListenView Earnings Details
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Edge Therapeutics (NASDAQ:EDGE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Edge Therapeutics (NASDAQ EDGE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.10%
Institutional Ownership Percentage: 33.67%
Insider Trading History for Edge Therapeutics (NASDAQ:EDGE)
Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ EDGE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/21/2018R. Loch MacdonaldInsiderSell2,500$16.52$41,300.00580,602View SEC Filing  
3/19/2018R. Loch MacdonaldInsiderSell2,500$16.66$41,650.00580,602View SEC Filing  
3/1/2018Brian A LeuthnerCEOSell2,500$14.81$37,025.0072,736View SEC Filing  
2/22/2018R. Loch MacdonaldInsiderSell2,500$14.49$36,225.00590,602View SEC Filing  
2/20/2018R. Loch MacdonaldInsiderSell5,000$13.75$68,750.00590,602View SEC Filing  
2/1/2018Brian A LeuthnerCEOSell2,500$13.14$32,850.0082,736View SEC Filing  
1/3/2018Brian A LeuthnerInsiderSell5,000$10.11$50,550.0087,736View SEC Filing  
12/5/2017Brian A LeuthnerInsiderSell7,500$9.86$73,950.0095,236View SEC Filing  
12/1/2017Brian A LeuthnerCEOSell2,500$9.92$24,800.0095,236View SEC Filing  
11/22/2017Albert N. Marchio IIInsiderSell3,361$10.00$33,610.00View SEC Filing  
11/3/2017Brian A LeuthnerInsiderSell7,500$10.91$81,825.00102,736View SEC Filing  
11/1/2017Brian A LeuthnerCEOSell2,500$10.92$27,300.00102,736View SEC Filing  
10/4/2017Brian A LeuthnerInsiderSell7,500$10.96$82,200.00View SEC Filing  
10/3/2017Brian A LeuthnerCEOSell2,500$10.93$27,325.00110,236View SEC Filing  
10/2/2017Brian A LeuthnerCEOSell2,500$10.81$27,025.00110,236View SEC Filing  
9/6/2017Brian A LeuthnerInsiderSell7,500$10.21$76,575.00117,736View SEC Filing  
9/5/2017Brian A LeuthnerCEOSell2,500$9.94$24,850.00117,736View SEC Filing  
9/1/2017Brian A LeuthnerCEOSell2,500$10.37$25,925.00117,736View SEC Filing  
8/29/2017Albert N Marchio IIInsiderSell2,500$10.42$26,050.003,361View SEC Filing  
8/23/2017Albert N Marchio IIInsiderSell1,000$10.39$10,390.005,861View SEC Filing  
8/3/2017Brian A LeuthnerInsiderSell7,500$10.53$78,975.00125,236View SEC Filing  
7/6/2017Brian A LeuthnerInsiderSell7,500$10.19$76,425.00132,736View SEC Filing  
3/6/2017James J LoughlinDirectorBuy3,000$9.24$27,720.0019,625View SEC Filing  
2/7/2017Brian A LeuthnerInsiderSell1,500$9.52$14,280.00245,479View SEC Filing  
2/6/2017Brian A LeuthnerInsiderSell3,000$9.61$28,830.00248,479View SEC Filing  
2/2/2017Brian A LeuthnerInsiderSell3,000$9.50$28,500.00251,479View SEC Filing  
12/1/2016Brian A LeuthnerInsiderSell7,500$11.60$87,000.00252,979View SEC Filing  
10/3/2016Brian A LeuthnerInsiderSell7,500$10.25$76,875.00260,479View SEC Filing  
8/8/2016W Bradford MiddlekauffVPBuy10,000$9.48$94,800.009,857View SEC Filing  
8/1/2016Brian A LeuthnerInsiderSell7,500$9.54$71,550.00267,979View SEC Filing  
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.0041,656View SEC Filing  
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Edge Therapeutics (NASDAQ EDGE) News Headlines

Source:
DateHeadline
Cutting Edge Healthcare Acquires Respiratory Therapeutics GroupCutting Edge Healthcare Acquires Respiratory Therapeutics Group
www.streetinsider.com - May 25 at 9:07 AM
Analyzing MediciNova (MNOV) and Edge Therapeutics (EDGE)Analyzing MediciNova (MNOV) and Edge Therapeutics (EDGE)
www.americanbankingnews.com - May 23 at 5:39 AM
The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Edge Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of June 22, 2018 (EDGE)The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Edge Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of June 22, 2018 (EDGE)
finance.yahoo.com - May 22 at 4:34 PM
BAS Research Signs Agreement With Dr. Kerklaan Therapeutics for California Manufacturing RightsBAS Research Signs Agreement With Dr. Kerklaan Therapeutics for California Manufacturing Rights
www.prnewswire.com - May 22 at 9:04 AM
Week 21 Breakout Forecast: Short-Term Picks To Give You An EdgeWeek 21 Breakout Forecast: Short-Term Picks To Give You An Edge
www.msn.com - May 21 at 9:02 AM
EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Edge Therapeutics, Inc.EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Edge Therapeutics, Inc.
finance.yahoo.com - May 18 at 4:51 PM
EDGE Deadline: Bernstein Liebhard LLP Reminds Investors Of Important Deadline In Class Action Against Edge Therapeutics, Inc. - EDGEEDGE Deadline: Bernstein Liebhard LLP Reminds Investors Of Important Deadline In Class Action Against Edge Therapeutics, Inc. - EDGE
finance.yahoo.com - May 18 at 4:51 PM
Mid-Morning Market Update: Markets Edge Higher; Walmart Tops Q1 ViewsMid-Morning Market Update: Markets Edge Higher; Walmart Tops Q1 Views
www.benzinga.com - May 17 at 5:09 PM
EDGE DEADLINE: Pawar Law Reminds Investors of Important June 22, 2018 Lead Plaintiff Deadline in Class Action- EDGEEDGE DEADLINE: Pawar Law Reminds Investors of Important June 22, 2018 Lead Plaintiff Deadline in Class Action- EDGE
finance.yahoo.com - May 17 at 5:09 PM
EDGE EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Edge Therapeutics, Inc. and a Lead Plaintiff Deadline of June 22, 2018EDGE EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Edge Therapeutics, Inc. and a Lead Plaintiff Deadline of June 22, 2018
finance.yahoo.com - May 17 at 5:09 PM
Quentis Therapeutics Announces the Appointment of Jeanne Magram, Ph.D. as Chief Scientific OfficerQuentis Therapeutics Announces the Appointment of Jeanne Magram, Ph.D. as Chief Scientific Officer
www.bizjournals.com - May 16 at 9:26 AM
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Edge Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of June 22, 2018 (EDGE)The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Edge Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of June 22, 2018 (EDGE)
finance.yahoo.com - May 15 at 5:03 PM
IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmIMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 15 at 5:03 PM
EDGE INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Edge Therapeutics, Inc. and a Lead Plaintiff Deadline of June ...EDGE INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Edge Therapeutics, Inc. and a Lead Plaintiff Deadline of June ...
www.businesswire.com - May 15 at 9:42 AM
Global Parkinson’s Disease Therapeutics Market Will Reach USD 4.31 Billion by 2023: Zion Market ResearchGlobal Parkinson’s Disease Therapeutics Market Will Reach USD 4.31 Billion by 2023: Zion Market Research
globenewswire.com - May 14 at 9:55 AM
Edge Therapeutics (EDGE) Short Interest UpdateEdge Therapeutics (EDGE) Short Interest Update
www.americanbankingnews.com - May 13 at 1:41 AM
EDGE LOSS NOTICE: Rosen Law Reminds Edge Therapeutics, Inc. Investors of Important Deadline in Class Action – EDGEEDGE LOSS NOTICE: Rosen Law Reminds Edge Therapeutics, Inc. Investors of Important Deadline in Class Action – EDGE
finance.yahoo.com - May 12 at 9:49 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Edge Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2018EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Edge Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2018
finance.yahoo.com - May 11 at 4:46 PM
PAWAR LAW - Edge Therapeutics, Inc. - June 22, 2018 Deadline in Class Action - EDGEPAWAR LAW - Edge Therapeutics, Inc. - June 22, 2018 Deadline in Class Action - EDGE
finance.yahoo.com - May 11 at 10:01 AM
Edge Therapeutics (EDGE) to Review of Strategic AlternativesEdge Therapeutics (EDGE) to Review of Strategic Alternatives
www.streetinsider.com - May 10 at 4:51 PM
Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as Chief Executive Officer and PresidentSemma Therapeutics Appoints Bastiano Sanna, Ph.D. as Chief Executive Officer and President
www.businesswire.com - May 10 at 9:26 AM
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmSHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 9 at 4:43 PM
The Klein Law Firm Announces a Class Action Filed on Behalf of Edge Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of June 22, 2018 (EDGE)The Klein Law Firm Announces a Class Action Filed on Behalf of Edge Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of June 22, 2018 (EDGE)
finance.yahoo.com - May 9 at 4:43 PM
EDGE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Edge Therapeutics, Inc. and a Lead Plaintiff Deadline of ...EDGE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Edge Therapeutics, Inc. and a Lead Plaintiff Deadline of ...
www.businesswire.com - May 9 at 9:16 AM
SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmSHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 9 at 9:16 AM
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmIMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 7 at 4:50 PM
Edge Therapeutics (EDGE) Lifted to "Hold" at ValuEngineEdge Therapeutics (EDGE) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - May 3 at 10:55 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Edge Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2018INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Edge Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2018
finance.yahoo.com - May 3 at 4:36 PM
Edge Therapeutics (EDGE) Releases Quarterly  Earnings Results, Misses Expectations By $0.14 EPSEdge Therapeutics (EDGE) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS
www.americanbankingnews.com - May 2 at 5:12 PM
Shareholders Foundation, Inc.: Lawsuit for Investors in Edge Therapeutics, Inc. (NASDAQ: EDGE) Shares Announced by Shareholders FoundationShareholders Foundation, Inc.: Lawsuit for Investors in Edge Therapeutics, Inc. (NASDAQ: EDGE) Shares Announced by Shareholders Foundation
www.finanznachrichten.de - May 2 at 4:44 PM
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmSHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 2 at 4:44 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Edge Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2018SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Edge Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2018
feeds.benzinga.com - May 2 at 1:55 PM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Edge Therapeutics, Inc. (EDGE)The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Edge Therapeutics, Inc. (EDGE)
www.businesswire.com - May 2 at 9:10 AM
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Edge Therapeutics, Inc. - EDGESHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Edge Therapeutics, Inc. - EDGE
finance.yahoo.com - May 1 at 4:35 PM
BRIEF-Edge Therapeutics Reports Quarterly Loss Per Share $0.67BRIEF-Edge Therapeutics Reports Quarterly Loss Per Share $0.67
www.reuters.com - May 1 at 9:14 AM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Edge Therapeutics, Inc. (EDGE)The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Edge Therapeutics, Inc. (EDGE)
finance.yahoo.com - May 1 at 9:14 AM
Edge Therapeutics Reports First Quarter 2018 Financial ResultsEdge Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 1 at 9:14 AM
Edge Therapeutics: 1Q Earnings SnapshotEdge Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 1 at 9:14 AM
Week 18 Breakout Forecast: Short-Term Picks To Give You An EdgeWeek 18 Breakout Forecast: Short-Term Picks To Give You An Edge
seekingalpha.com - April 30 at 4:37 PM
Edge Therapeutics to explore strategic alternative; shares down 3%Edge Therapeutics to explore strategic alternative; shares down 3%
seekingalpha.com - April 30 at 4:37 PM
Edge Shareholders: Bernstein Liebhard LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Edge Therapeutics, Inc. - EDGEEdge Shareholders: Bernstein Liebhard LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Edge Therapeutics, Inc. - EDGE
finance.yahoo.com - April 30 at 4:37 PM
MabVax Therapeutics to Present an Interactive Live Webcast at VirtualInvestorConferences.comMabVax Therapeutics to Present an Interactive Live Webcast at VirtualInvestorConferences.com
www.bizjournals.com - April 30 at 9:22 AM
Edge Therapeutics Announces Review of Strategic AlternativesEdge Therapeutics Announces Review of Strategic Alternatives
finance.yahoo.com - April 30 at 9:22 AM
EDGE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Edge Therapeutics, Inc. To Contact The FirmEDGE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Edge Therapeutics, Inc. To Contact The Firm
finance.yahoo.com - April 28 at 9:35 AM
INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Edge Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 27 at 4:38 PM
Robbins Arroyo LLP: Edge Therapeutics, Inc. (EDGE) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Edge Therapeutics, Inc. (EDGE) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - April 27 at 9:44 AM
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Edge Therapeutics, Inc.SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Edge Therapeutics, Inc.
finance.yahoo.com - April 26 at 4:38 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Edge Therapeutics, Inc. (EDGE) & Lead Plaintiff Deadline - June 25, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Edge Therapeutics, Inc. (EDGE) & Lead Plaintiff Deadline - June 25, 2018
finance.yahoo.com - April 26 at 4:38 PM
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Edge Therapeutics, Inc.Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Edge Therapeutics, Inc.
finance.yahoo.com - April 26 at 4:38 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Edge Therapeutics, Inc. -- EDGEINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Edge Therapeutics, Inc. -- EDGE
www.businesswire.com - April 25 at 4:48 PM

SEC Filings

Edge Therapeutics (NASDAQ:EDGE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Edge Therapeutics (NASDAQ:EDGE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Edge Therapeutics (NASDAQ EDGE) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.